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studiesAbstract A novel, selective and sensitive reverse phase-high performance liquid chromatography
(RP-HPLC) method has been developed for the validated estimation of imidazol-1-yl-acetic acid
in zoledronic acid formulations. The separation was achieved on a 5 l C18 column
(250 · 4.6 mm) using a mobile phase that consists of the buffer (4.5 g of di-potassium hydrogen
phosphate anhydrous and 2.0 g of tetra butyl ammonium hydrogen sulphate (TBAHS) in
1000 mL of water) and methanol in the ratio of 900:100 v/v. The ﬂow rate was maintained at
1.0 mL min1. The detection of the constituents was done at 215 nm using a UV detector. The
retention times of imidazol-1-yl-acetic acid and zoledronic acid were 7.2 and 10.2 min respectively.
Recovery studies were satisfactory and the correlation coefﬁcient, 0.999 indicates linearity of the
method within the limits. The developed method can be applicable for regular qualitative analysis.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Zoledronic acid is a nitrogen containing bisphosphonic acid,
widely used to prevent or treat osteoporosis in post-meno-
pausal women, in men or women who have taken glucocorti-
coids (a type of corticosteroid medication that may cause
osteoporosis), paget’s disease of the bone (a condition in whichthe bones are soft and weak, and may be deformed, painful or
easily breakable), high levels of calcium in the blood may occur
with certain types of cancer, due to its high potential and
inhibits osteoclastic bone resorption (Adami et al., 2002;
Amanat et al., 2007; Andrew et al., 2008; Aparicio et al.,
1998; Berenson, 2005; Black et al., 2007; Body et al., 1999;
Boutsen et al., 2001; Conte and Guarneri, 2004).
The literature survey reveals that HPLC and RP-HPLC for
determination of zoledronic acid are reported (Jiang et al.,
2004; Mallikarjuna Rao et al., 2005; Praveen Kumar and Sree-
ramulu, 2011; Srinivasan Raghu Nandan et al., 2009; Jiang
et al., 2005; Zhang et al., 2004; Matuszewski et al., 2011).
But, a few are (Praveen Kumar and Sreeramulu, 2011; Sriniva-
san Raghu Nandan et al., 2009; Zhang et al., 2004) about sta-
bility indicating reverse phase high-performance liquid
chromatography (RP-HPLC) methods for the determination
A simple RP-HPLC method for related substances of zoledronic acid in pharmaceutical products S197of zoledronic acid in pharmaceutical injections/tablets. Even
for though those who are suffering from interference of
impurities/intermediates when forced to stress conditions the
method becomes less sensitive with low selectivity. Therefore,
the development of a new economical, selective and sensitive
RP-HPLC method for zoledronic acid and its related sub-
stances is intended.
The main objective of this study was to develop a novel, sim-
ple, economical, selective, sensitive and stablemethod indicating
the use of reverse phase-high performance liquid chromatogra-
phy (RP-HPLC) method for the assay of zoledronic acid and
its related substances, imidazol-1-yl-acetic acid (Fig. 1) present
in pharmaceutical products using aUVdetector. It was included
in the performance of stress/inﬂuenced factors, such as acid or
base hydrolysis, hydrogen peroxide oxidation, light and heat
on zoledronic acid and its related substances, inimidazol-1-yl-
acetic acid determination. This paper also deals with the validity
of the proposedmethod for the accurate estimation of zoledron-
ic acid and related substances in pharmaceutical samples. The
mobile phase was used as diluent for the preparation of working
solutions, whichminimizes errors that occur in quantitative sep-
aration techniques. This proposed method was successfully ap-
plied for regular analysis.
2. Materials and methods
2.1. Reagents
Dipotassium hydrogen phosphate anhydrous (Merck, GR
Grade), tetra butyl ammonium hydrogen sulphate (TBAHS)
(Merck, German, Catalogue. No. 8.18858.0100/synthesis
grade), methanol (HPLC grade), water (HPLC grade), phos-
phoric acid 85% pure (Merck grade) was used in the present
study. All other chemicals used were of analytical reagent
grade, otherwise stated.
2.2. Chromatographic system conditions
Kromosil 5 l C18 column (250 · 4.6 mm) at 323 K oven tem-
perature for 45 min (for blank, sample preparation), and
15 min (for standard preparation) run time with 1.0 mL min1
ﬂow rate was used for the separation of impurities in zoledron-
ic acid or related substances and detected at 215 nm using a
UV detector. 15 lL of sample was used for the injection into
the column. Water and mobile phases were used as diluents.
2.3. Preparation of mobile phase
Accurately weighed 4.5 g of dipotassium hydrogen phosphate
anhydrous and 2.0 g of tetra butyl ammonium hydrogenZoledronic acid
N
N
Imidazol-1-yl-acetic acid
OH
O
Figure 1 Chemical structure of zoledronic acid and impurity
(Imidazol-1-yl-acetic acid).sulphate in a 1000 mL glass beaker, added 1000 mL of water,
and sonicated for 10 min on occasional stirring with a glass
rod. Well mixed buffer and methanol in the ratio of 900:100
v/v was used as the mobile phase.
2.4. Impurity (20 lg mL1) and standard (32 lg mL1) stock
solution preparation
Accurately weighed and transferred 2.0 mg of imidazol-1-
yl-acetic acid impurity into a 100 mL volumetric ﬂask, dis-
solved 70 mL of the mobile phase and made up to the mark
with mobile phase and used as impurity stock.
Weighed accurately about 21.4 mg of zoledronic acid
monohydrate (equivalent to 20.0 mg of zoledronic acid) into
a 25 mL volumetric ﬂask, added about 20 mL of mobile phase,
sonicated to dissolve for about 15 min with occasional shaking
and diluted to volume with mobile phase and mixed well,
which is used as a stock standard. Pipette out 1.0 mL of the
above solution into a 25 mL volumetric ﬂask and dilute to vol-
ume with mobile phase.
2.5. Standard and test solution preparation
Pipette out 2.0 mL each of the above standard stock solution
and impurity stock solution into a 25 mL volumetric ﬂask
and made up with diluents for making a standard solution.
Opened ﬁve vials (each vial contains zoledronic acid: 4 mg
5 mL1). Pooled the content of each individual vial into a
clean and dried 50 mL volumetric ﬂask or into a dried
25 mL stoppered test tube and mixed well with diluents. This
solution was used as test solution for further studies.
2.6. System suitability
The relative standard deviation for zoledronic acid or imida-
zol-1-yl-acetic acid peak area and peak area of six replicate
injections should not be more than 10.0%; The tailing factor
for zoledronic acid and imidazol-1-yl-acetic acid peaks should
not be more than 2.0; The column efﬁciency (theoretical plates)
for zoledronic acid and imidazol-1-yl-acetic acid peaks that
should be not less than 2000 is necessary for good system suit-
ability. For good system suitability to determine imidazole-1-
yl-acetic acid less than 10% RSD, less than tailing factor
and more than 2000 theoretical plates were maintained.
The presence of imidazol-1-yl-acetic acid content in the
pharmaceutical samples was calculated using the following
formula.
% Of imidazol-1-yl-acetic acid:
AWi  2 Pi
Si  100 25 0:8
% Of any unknown impurity:
BWs 1 2 Ps
Ss 25 25 25 0:8
where, A=peak area of imidazol-1-yl-acetic acid for test prep-
aration; B=peak area of any impurity other than blank, pla-
cebo, imidazol-1-yl-acetic acid and zoledronic acid for test
preparation,Wi =weight of imidazol-1-yl-acetic acid impurity
taken in mg for standard preparation; Ws =Weight of zoled-
ronic acid monohydrate working standard taken in mg for
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Figure 2 (A) Blank/diluents, (B) standard solution and (C) test solution chromatogram.
Table 1 Study of system precision.
Injection
Number
Zoledronic
acid peak
area
Imidazol-1-yl-
acetic acid peak
area
Acceptance criteria
01 29270 43563 The relative standard deviation of peak areas of zoledronic acid
and imidazol-1-yl-acetic acid peak area should not be more than
10.0%.
02 28683 43546
03 28505 43575
04 28101 43621
05 27747 43396
06 27329 43474
Mean 28272 43529
%RSD 2.5 0.2
S198 L. Maheswara Reddy et al.
Table 2 Study of system suitability.
System suitability for standard preparation Observed value Acceptance criteria
The tailing factor for peaks Zoledronic acid 1.09 Should not be more than 2.0
Imidazol-1-yl-acetic acid 1.10
The column eﬃciency for standard peaks Zoledronic acid 13788 Should not be less than 2000
Imidazol-1-yl-acetic acid 16278
Table 3 Forced degradation studies on zoledronic acid.
Stress condition Drug product
% Degradation Zoledronic acid
Purity angle Purity threshold Purity ﬂag
Acid degradation (1.0 mol L1 HCl at 353Kon water bath for 6 h) 0.0 0.447 1.393 NO
Base degradation (1.0 mol L1 NaOH at 353 K on water bath for 6 h) 0.0 0.706 1.476 NO
Peroxide degradation (10% H2O2 at 353 K on water bath for 6 h) 1.91 0.455 1.309 NO
UV degradation (P200 wh/m2 at 298 K with UV radiation at 320–420 nm) 0.0 0.352 1.299 NO
Thermal degradation (363 K for 6 h) 0.0 0.506 1.401 NO
Sunlight degradation (24 h) 0.0 0.450 1.326 NO
Un stressed sample 0.0 0.445 1.347 NO
A simple RP-HPLC method for related substances of zoledronic acid in pharmaceutical products S199standard preparation; Pi = Purity of imidazol-1-yl-acetic acid
impurity in %; Ps = Potency of zoledronic acid monohydrate
working standard as zoledronic acid in %; Si = Peak area of
imidazol-1-yl-acetic acid for diluted standard preparation;
Ss = Peak area of zoledronic acid for standard preparation;
0.8 = Label claim of zoledronic acid in mg mL1.
3. Results and discussion
3.1. System precision and suitability
A standard solution was prepared by mixing the working stan-
dard (zoledronic acid monohydrate) and imidazol-1-yl-acetic
acid impurity as per the test method and was injected six times
into the HPLC system. The system suitability parameters were
evaluated from the standard chromatogram for both zoledron-
ic acid and imidazol-1-yl-acetic acid and the results are illus-
trated in Fig. 2. The system suitability was found to be
within the limits. Fig. 2 represents the diluents, standard solu-
tion and test solution chromatograms. System suitability re-
sults and precision results are also tabulated in Tables 1 and
2. The obtained results were within the limits, indicating that
the system is more precise with good suitability.
3.2. Speciﬁcity
3.2.1. Placebo interference
A study to establish the interference of placebo was performed.
Placebo solution was injected in triplicate as per the test meth-
od. Chromatogram of placebo did not show any peak at the
retention time of zoledronic acid and imidazol-1-yl-acetic acid.
This indicates that the excipients used in the injection formula-
tion (zoledronic acid injection 4.0 mg 5 mL1) do not interfere
in the estimation of related substances of zoledronic acid.
3.2.2. Interference from degradation products
A study was conducted to demonstrate the effective separation
of degradants/impurities from zoledronic acid. Separateportions of sample bulk solution and placebo solutions were
exposed to the following stress conditions to induce degrada-
tion. Stressed and unstressed samples were injected into the
HPLC system with photo diode array detector by following
test method conditions. All degrading peaks were resolved
from zoledronic acid peak in the chromatograms of all samples
and placebo did not show any interference at the retention
time of zoledronic acid and imidazol-1-yl-acetic acid under
the above conditions. Degradation study results were pre-
sented in Table 3 and chromatograms were shown in Fig. 3.
From the results, the determination of zoledronic acid was
not affected with any stress/inﬂuenced factor, but moderately
affected with the oxidation conditions, especially, 10% hydro-
gen peroxide at 353 K oxidation of zoledronic acid shifted its
peak to a lower retention time from its regular one
(Fig. 3(C)). The remaining forced conditions were not affected
bythe retention time and peak area of zoledronic acid and its
related substances.3.3. Precision and accuracy of the test method
The precision of the method was evaluated by analysing six
samples which were prepared as per the test method by spiking
imidazol-1-yl-acetic acid at 0.2% of target test concentration
(800 lg mL1) in the presence of sample bulk solution.
The percentage of relative standard deviation for imidazol-1-
yl-acetic acid was calculated and the results were found to be
within the limits (Table 4). Hence, the results indicated that
the method was more precise.
An accuracy study of imidazol-1-yl-acetic acid from spiked
samples of zoledronic acid was conducted. Samples were pre-
pared in triplicate at each level by spiking imidazol-1-yl-acetic
acid in the presence of sample bulk solution at 50%, 75%,
100%, 125%, and 150% to the target concentration (0.2%).
The percentage recovery and average percentage recovery for
impurity was found to be within the limits and the results
are shown in Table 5.
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Figure 3 Forced degradation/stability studies of zoledronic acid with (A) acid stressed, (B) base stress, (C) peroxide stress, (D) UV light
stress, (E) thermal stress, (F) sun light stress, (G) un stressed chromatogram.
S200 L. Maheswara Reddy et al.3.4. Linearity of the test method
A linearity graph was plotted for average ‘lg mL1’ of imida-
zol-1-yl-acetic acid added against average ‘lg mL1’ of imida-
zol-1-yl-acetic acid found in the accuracy section. The
correlation coefﬁcient (0.999) was found to be within the limits
indicating that the test method was linear for test sample deter-
minations, which is shown in Fig. 4.3.5. Limit of detection (LOD) and limit of quantiﬁcation
(LOQ)
A study to establish the limit of detection and limit of quanti-
ﬁcation of imidazol-1-yl-acetic acid was conducted. Limit of
detection (LOD) and limit of quantiﬁcation (LOQ) were estab-
lished based on the signal to noise ratio. A series of solutions
having different concentrations (range) of imidazol-1-yl-acetic
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Fig. 3 (continued)
A simple RP-HPLC method for related substances of zoledronic acid in pharmaceutical products S201acid were prepared by spiking the impurity in the presence of
sample bulk solution and were injected. Limit of detection was
established by identifying the concentration, which gives signal
to noise ratio of about 3.0. Limit of quantiﬁcation for the
impurity was established by identifying the concentration,
which gives signal to noise ratio of about 10. For testing
LOD and LOQ six samples were prepared by spiking imida-
zol-1-yl-acetic acid (0.04 lg mL1 and 0.16 lg mL1 for testing
LOD and LOQ respectively) to the solution which was pre-
pared in precision and accuracy of impurity determination
experiments at about the limit of quantiﬁcation and detection
in the presence of sample bulk solution as per the test methodand were injected into HPLC. The obtained results found
0.005% and 0.02% at LOD and LOQ with 3.5 and 14.0 signal
to noise ratio respectively.
3.6. Linearity of detector response
A linearity study of detector response (Area) versus concentra-
tion (lg mL1) of imidazol-1-yl-acetic acid was conducted. A
series of solutions of imidazol-1-yl-acetic acid in the concentra-
tion range of about limit of detection quantity (LOQ) level to
200% of target concentration (0.2%) were prepared and in-
jected into the HPLC system. The detector response was found
Table 4 Precision study of the method.
Sample RRT Imidazol-1-yl-acetic acid
Peak area % Imp
01 0.75 43476 0.195
02 0.74 43701 0.196
03 0.74 43665 0.195
04 0.74 43621 0.195
05 0.75 43787 0.196
06 0.75 44170 0.198
Average 0.75 – 0.196
%RSD – – 0.59
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Fig. 3 (continued)
S202 L. Maheswara Reddy et al.to be linear from LOQ to 200% of the target concentration
and the correlation coefﬁcient was found to be within the
limits.
3.7. Range, precision and accuracy
A study of range for imidazol-1-yl-acetic acid was conducted
for precision, accuracy and linearity. The range of the test
method was evaluated by analysing the following parameters.Table 5 Recovery results of imidazol-1-yl-acetic acid from zoledro
Sample No. Spike level (%) Added, ‘lg mL1’ R
1 50 0.814 0.
2 50 0.
3 50 0.
1 75 1.221 1.
2 75 1.
3. 75 1.
1 100 1.629 1.
2 100 1.
3 100 1.
1 125 2.036 2.
2 125 2.
3 125 2.
1 150 2.443 2.
2 150 2.
3 150 2.Samples were prepared six times by spiking imidazol-1-yl-
acetic acid at the limit of quantiﬁcation (LOQ) and 150% of
target concentration (0.2%) and were injected into the HPLC
system. The calculated relative standard deviation for the impu-
rity at the limit of detection quantity (LOQ) level with 150%
target spiked level. The % of RSD of individual impurities at
LOQ level with 150% spiked level was found to be within the
limits.
Samples were prepared in triplicate at lower spiked level
(LOQ level) with highest spiked level (150%) to the target con-
centration of imidazol-1-yl-acetic acid. The percentage of
recoveries and average percentage of recoveries were found
to be within the limits.
3.8. Ruggedness of the test method
3.8.1. System to system/analyst to analyst/column to column
variability
System to system/analyst-to-analyst/column to column vari-
ability study was conducted on different HPLC systems, differ-
ent columns, on different days and by different analysts under
similar conditions at different times. Six samples were pre-
pared as per the test method by spiking imidazol-1-yl-acetic
acid at 0.2% of the target test concentration (800 lg mL1)nic acid.
ecovered, ‘lg mL1’ % Recovery Mean % Recovery
838 102.9 103.2
842 103.4
841 103.3
259 103.1 102.9
252 102.5
258 103.0
627 99.9 100.2
635 100.4
636 100.4
128 104.5 104.4
123 104.3
126 104.4
497 102.2 102.1
482 101.6
504 102.5
Figure 4 Linearity graph of imidazol-1-yl-acetic acid.
A simple RP-HPLC method for related substances of zoledronic acid in pharmaceutical products S203in the presence of sample bulk solution. The percentage of rel-
ative standard deviation for imidazol-1-yl-acetic acid was cal-
culated and the results were found to be within the limits.
Comparison of both the results obtained on two different
HPLC systems, different columns and different analysts shows
that the related substances test method is rugged for system to
system/analyst to analyst/column to column variability.
3.8.2. Bench top stability of standard and test preparation
A study to establish the analytical solution stability of the stan-
dard and test preparations on bench top was conducted over a
period of 48 h. Standard preparation and test preparation with
impurities spiked at target concentration were injected at ini-
tial, 24 and 48 h. The difference in the % of known individual
impurities and the % of total impurities from initial to 48 h
was within the limits. From the above study, it was established
that the standard and sample solutions were stable for 48 h on
bench top.
3.8.3. Bench top stability of mobile phase
A study to establish the bench top stability of the mobile phase
for a period of about 2 days was conducted. Standard prepara-
tion and test preparation with impurities spiked at target con-
centration were injected at initial, 24 and 48 h. The difference
in the percentage of known individual impurities and the per-
centage of total impurities from initial to 48 h was within the
limits. From the above study, it was established that the mo-
bile phase was stable for 48 h on bench top.
3.9. Robustness
3.9.1. Effect of variation of ﬂow rate
A study was conducted to determine the effect of variation in
the ﬂow rate. Standard solution prepared as per the test meth-
od was injected into the HPLC system using ﬂow rates of 0.6
and 1.0 mL min1 instead of 0.8 mL min1. The system suit-
ability parameters were evaluated and found to be within the
limits for 0.6 and 1.0 mL min1 ﬂow. Test solution was pre-
pared as per the test method by spiking imidazol-1-yl-acetic
acid at 0.2% of target concentration (800 lg mL1) in the pres-
ence of sample bulk solution and was injected into the HPLC
system using ﬂow rates of 0.6 and 0.8 mL min1 ﬂow. Imida-
zol-1-yl-acetic acid was well resolved from all other peaks
and the relative retention times were comparable with those
obtained for the mobile phase having ﬂow rates of 0.6 and
1.0 mL min1. From the above study it was established that
the allowable variation in ﬂow rates is 0.6 and 1.0 mL min1.
3.9.2. Effect of column oven temperature variation
A study was conducted to determine the effect of variation in
column temperature. Standard solution prepared as per the
test method was injected into the HPLC system by thermo
setting the column oven temperature at 318 and 328 K in-
stead of 323 K. The system suitability parameters were eval-
uated and found to be within the limits for 318 and 328 K.
Test solution was prepared as per the test method by spiking
imidazol-1-yl-acetic acid at 0.2% of the target concentration
(800 lg mL1) in the presence of sample bulk solution and
was injected into the HPLC system, keeping the column oven
temperatures at 318 and 328 K. Imidazol-1-yl-acetic acid waswell resolved from all other peaks and the relative retention
times were comparable with those obtained for the column
temperatures 318 and 328 K. From the above study it was
established that the allowable variation in column oven tem-
perature is 318–328 K.
3.9.3. Effect of variation in the mobile phase composition
A study was conducted to determine the effect of variation of
mobile phase composition. Prepared standard solution was in-
jected into the HPLC system using two different mobile
phases. The system suitability parameters were evaluated and
found to be within the limits for the mobile phase having
90% and 110% of the method organic phase. Test solution
was prepared as per the test method by spiking imidazol-1-
yl-acetic acid at 0.2% of target concentration (800 lg mL1)
in the presence of the sample bulk solution and was injected
into the HPLC system using a mobile phase having 90% and
110% of the method organic phase separately. Imidazol-1-yl-
acetic acid was well resolved from all other peaks and the rel-
ative retention times were comparable with those obtained
from the actual method. From the above study it was estab-
lished that the allowable variation in organic phase composi-
tion in the mobile phase is 90% to 110% of the method
organic phase of the mobile phase.3.9.4. Effect of variation of pH
A study was conducted to determine the effect of variation in
pH. Standard solution prepared as per the test method was
injected into the HPLC system using the mobile phase at
pH 7.0 and 7.4. The system suitability parameters were
evaluated and found to be within the limits for 7.0 and 7.4.
Test solution was prepared as per the test method by spiking
imidazol-1-yl-acetic acid at 0.2% of target concentration
(800 lg mL1) in the presence of sample bulk solution and
was chromatographed using mobile phase at pH 7.0 and
7.4. Iimidazol-1-yl-acetic acid was well resolved from all
other peaks and the relative retention times were comparable
with those obtained for mobile phase having pH 7.0 and 7.4.
From the above study it concluded that the allowed variation
in the mobile phase pH is 7.0 and 7.4.
S204 L. Maheswara Reddy et al.3.10. Advantages of the present RP-HPLC method
The present method is highly precise and accurate when com-
pared with other existing RP-HPLC methods (Srinivasan Rag-
hu Nandan et al., 2009). The present method can be performed
more effectively even in the presence of degradation/stress fac-
tors, such as UV-light, sun light and high temperature condi-
tions, except hydrogen peroxide for the separation and
determination of zoledronic acid and its related substance, Ii-
midazol-1-yl-acetic acid (Jiang et al., 2004, 2005; Zhang
et al., 2004), even though, it also showed good performance
with high resolution up to 10% hydrogen peroxide without
any impurity ﬂag. The resolution of the zoledronic acid peak
in the present method is 3.0 from its adjacent peaks, which
was more than the reported methods (Jiang et al., 2004,
2005; Mallikarjuna Rao et al., 2005; Praveen Kumar and Sree-
ramulu, 2011; Zhang et al., 2004). Iimidazol-1-yl-acetic acid
was well resolved from all other peaks and the relative reten-
tion times were comparable with those obtained for mobile
phases having pH 7.0 and 7.4.The present method is more eco-
nomical when compared with other existing methods where
there is more chemical consumption (Matuszewski et al.,
2011). The mobile phase itself is used as a diluent in the present
method, which has minimized errors that occur in quantitative
analysis.
4. Conclusion
The above RP-HPLC analytical method satisﬁes all validation
parameters like system suitability, precision, speciﬁcity, accu-
racy, linearity of detector response, ruggedness (Analyst to
analyst, system to system and column to column variability,
bench top/ refrigerator stability) and robustness (mobile phase
composition variation, variation in ﬂow rate, temperature
variation). At the same time the method satisﬁes the forced
degradation study. It indicates that the method is more stable
and suitable for the zoledronic acid and its related substances
determination. Hence, the method can be used for the estima-
tion of zoledronic acid injection 4 mg 5 mL1 in regular
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